» Articles » PMID: 20408955

Patients with Isolated Polycystic Liver Disease Referred to Liver Centres: Clinical Characterization of 137 Cases

Overview
Journal Liver Int
Specialty Gastroenterology
Date 2010 Apr 23
PMID 20408955
Citations 59
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aim: Isolated polycystic liver disease (PCLD) is characterized by the presence of multiple cysts in the liver in the absence of polycystic kidneys. The clinical profile of PCLD is poorly defined and we set up a study for the clinical characteristics of PCLD.

Methods: We collected clinical data on 188 PCLD patients (defined as >10 liver cysts) from five tertiary referral centres, and 137 patients were selected for the purpose of this study. We performed molecular analysis of the PCLD associated genes PRKCSH and SEC63 in 91 patients.

Results: A total of 118 (86%) patients were female. The majority of patients (88%) had >20 cysts. The median age at diagnosis was 47 years (range 23-84). 37 (41%) patients carried a mutation. Clinical symptoms at presentation were present in 111 (84%) patients. γ-glutamyl transferase was elevated to 1.4 times upper limit of normal (interquartile range 1.0-2.7). The presence of a mutation and female gender predicted a more severe course: female patients were 9 years younger at the time of diagnosis (47 years; range 23-84) and 91% had symptoms (P<0.01); likewise, mutation carriers were younger at presentation (39 years; range 35-48) and 95% of this cohort had symptoms (P<0.01). During follow-up [median 8.2 years (range 0-35)], 10% of untreated and 51% of treated patients developed complications. Mortality in this cohort was 8%, but only 2% died of PCLD-related causes. 58% of patients were treated a median of 2 years (range 0-25) after diagnosis.

Conclusion: Symptomatic PCLD patients are mainly females. Females and mutation carriers were younger at diagnosis and had a more severe course of disease.

Citing Articles

Clinical manifestation, epidemiology, genetic basis, potential molecular targets, and current treatment of polycystic liver disease.

Mahboobipour A, Ala M, Safdari Lord J, Yaghoobi A Orphanet J Rare Dis. 2024; 19(1):175.

PMID: 38671465 PMC: 11055360. DOI: 10.1186/s13023-024-03187-w.


Liver transplant recipients with polycystic liver disease have longer waiting times but better long-term clinical outcomes than those with liver disease due to other causes: A retrospective cross-sectional study.

Gittus M, Moore J, Ong A PLoS One. 2024; 19(1):e0294717.

PMID: 38165905 PMC: 10760649. DOI: 10.1371/journal.pone.0294717.


Factors Associated With the Development and Severity of Polycystic Liver in Patients With Autosomal Dominant Polycystic Kidney Disease.

Kim Y, Park H, Ryu H, Kim Y, Ahn C, Lee K J Korean Med Sci. 2023; 38(38):e296.

PMID: 37750370 PMC: 10519778. DOI: 10.3346/jkms.2023.38.e296.


Liver transplantation for polycystic liver disease: a case report.

Niibek M, Uksov A J Surg Case Rep. 2023; 2023(9):rjad507.

PMID: 37724070 PMC: 10505486. DOI: 10.1093/jscr/rjad507.


Questionnaire PLD-complaint-specific assessment identifies need for therapy in polycystic liver disease: A multi-centric prospective study.

Billiet A, Temmerman F, Coudyzer W, Van den Ende N, Colle I, Francque S United European Gastroenterol J. 2023; 11(7):633-641.

PMID: 37278135 PMC: 10493353. DOI: 10.1002/ueg2.12387.